HERON’s heritage in scientific methodology, coupled with industry knowledge and insight, make for a superior review that is fundamental to a strong evidence case.  Our Evidence Review Practice operates throughout HERON’s global offices, with the addition of sizable offshore capacity offering focused expertise in the research and development of reviews that align sound evidence with a strong value proposition.

To engage HERON in a Request for Proposal for evidence development, click here

To review the levels of rigor available in HERON evidence review methodologies, click here

The role of evidence development and synthesis in the commercial development of your product or portfolio: How much and what type of evidence do you need?

HERON clients commission evidence reviews in a range of circumstances. They may have additional indications for an existing compound, a new competitive compound on the market, or new evidence about the positioning or effectiveness of their compound. Changes in reimbursement policy, the opportunity for a Health Technology Assessment submission, or internal business considerations may also trigger the need for a review.

HERON’s Evidence Review Practice is one of the largest and most experienced in the industry, drawing upon scientific rigor and proprietary methodologies that have satisfied the most stringent scrutiny for over a decade. Unique in approach, HERON offers evidence reviews as:

1. Single (one-off) evidence review projects, developed and delivered within a defined time period and customized to meet the level of rigor required by intended client outputs. To further clarify how HERON’s review service could meet your evidence needs click here, or alternatively, upload a Request for Proposal.
2. Product-focused Active Evidence Review™ Service (ongoing per product), benchmarked with the development of an initial robust review, updated quarterly thereafter via concise reporting to select internal stakeholders. Recommended for individual products/compounds in highly competitive landscapes, in consideration for multiple indications, and/or with outcomes and efficacy data that require broader context and consideration. To further clarify how this HERON service could meet your evidence needs, click here.
3. Therapy-focused Active Evidence Review™ Service (ongoing per therapy area or class), allows for economies of scale in research costs by generating evidence and providing synthesized reporting for team decision-making. Recommended for therapies in highly competitive landscapes and/or with outcomes and efficacy data requiring broader context and consideration. To further clarify how this HERON service could meet your evidence needs, click here.
4. Portfolio-focused Active Evidence Review™ Service (ongoing for a full therapeutic portfolio), realizes economies of scale in research costs and achieves evidence generation and reporting capabilities that keep a broad array of internal therapeutic team members and stakeholders informed and on-point with competitive positioning, value and effectiveness differentiators, and market access strategies/implementation. Highly recommended for robust portfolios looking to achieve and sustain market dominance and/or where outcomes and other data could benefit from broader context/consideration (e.g., infusing real-time patient-reported outcome data to quantify benefits to treatment). This is a unique and proprietary HERON offering that will satisfy the most stringent of requirements, coalesce evidence into smart synthesis for direction-setting, and realize both efficiency and effectiveness in research spending with prioritized output. To further clarify how this HERON service could meet your evidence needs, click here.